Semax: Neuroprotection and Cognitive Research on a Russian ACTH Analog

Semax has been given to stroke patients in Russia for roughly three decades. It also gets bought by biohackers as a cognitive enhancer. Those are two very different evidence stories wearing the same name, and the stroke data, the stronger of the two, still comes almost entirely from one country. That split is the thing to hold onto here.

What Semax is

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic seven-amino-acid peptide built from the 4-10 fragment of adrenocorticotropic hormone (ACTH). Researchers in the 1970s found that the ACTH 4-10 fragment carries the behavioural and brain-supporting (neurotrophic) effects of full ACTH without the cortisol-stimulating part. Semax bolts a proline-glycine-proline tail onto the end, which makes it resist enzyme breakdown and last longer in animals.

It’s a registered drug in Russia for cerebral ischemia and transient ischemic attacks, in clinical use there for about thirty years. That matters: this isn’t a pure research-stage compound. It’s been given to real patients in a regulated setting, which generates real-world tolerability data. The asterisk is that the regulator setting those standards isn’t the FDA.

The stroke data, and the nootropic data

The strongest human evidence is Russian clinical research in acute ischemic stroke. A 2006 paper in the Journal of Neurochemistry showed Semax binds specifically in rat basal forebrain and increases brain-derived neurotrophic factor (BDNF) protein levels there — describing it as a BDNF-mediated neurotrophic peptide that may act through several signalling pathways at once. May is doing the work in that sentence.

A 1997 clinical and electrophysiological study by Gusev et al. in the S.S. Korsakov journal of neurology and psychiatry reported Semax effectiveness in the acute period of hemispheric ischemic stroke, in a Russian clinical setting. The limits mirror Selank’s: one-country research ecosystem, variable study quality, little independent Western replication.

For cognitive enhancement, the evidence is mostly animal and pilot work. Semax raises BDNF in rodent hippocampal tissue and improves rodent learning and memory tasks. In rats. Whether any of that carries over to sharper thinking in healthy humans isn’t established by controlled trials. That’s the leap the biohacker use depends on, and it’s unproven.

The PCAC review — July 24

Semax is on the PCAC July 24, 2026 docket — Day 2 of the two-day meeting, alongside DSIP (Emideltide) and Epitalon. Per Federal Register notice 2026-07361, the FDA-reviewed indications for Semax are cerebral ischemia, migraine, and trigeminal neuralgia. The Day 1 substances — BPC-157, KPV, TB-500, and MOTS-c — were reviewed the day before for different indications.

A yes from PCAC wouldn’t approve Semax as a drug. It would set up a pathway for compounding pharmacies to prepare it legally for patients with valid prescriptions and the listed indications. The July 2026 outcome will substantially shape its US picture.

Semax isn’t on the FDA’s current 503A or 503B approved bulk substances list, so pharmacies selling it now operate under regulatory risk.

For athletes: Semax doesn’t appear by literal name on the WADA 2026 Prohibited List, but it’s a non-approved peptide with reported neurostimulant and BDNF-modulating activity. WADA’s S0 (non-approved substances) and S6 (stimulant) categories reach it. Treat it as prohibited, in and out of competition.

What’s still uncertain

The stroke-protection evidence, while more clinical than most peptides in this space, carries the same single-ecosystem limit as Selank and the other Russian-developed compounds. Independent Western replication at scale hasn’t happened.

The cognitive evidence is mostly preclinical. The BDNF rise seen in rodents hasn’t been reproduced in controlled human trials measuring cognition in healthy adults. Going from animal neurotrophin data to human mental performance is a long jump the existing evidence doesn’t support directly.

Best dose, route, and duration of effect for any human use haven’t been characterised in published Western pharmacokinetic studies. Nobody’s mapped it.

And the July 2026 PCAC review decides regulatory eligibility, not whether the drug works. Even a favourable vote won’t answer whether Semax does anything in the contexts the longevity crowd actually cares about.

What Semax is, on the eve of PCAC

Semax stands out for its Russian drug registration and decades of stroke-context clinical use, a more developed history than most compounds here. But the evidence is concentrated in one ecosystem, which is a real scientific limit, and the cognitive-enhancement use that draws the longevity community has no controlled human trial behind it.

The honest framing: the July 24, 2026 PCAC review will set the regulatory framework, the clinical questions stay open, and the stroke data and the nootropic data should never be quoted as if they’re the same thing.